Ticker ANIX – Anixa Biosciences – sales, description, marketcap – Tickerday.com

ANIX

Anixa Biosciences

–

Index: NASDAQ; Sector: Healthcare; Industry: Biotechnology & Drugs;

Marketcap: 61.14M; Volume: 39.67K; AvgVol 3m: 312.37K; Beta: 1.21;

Cost estimate:

P/E: –; EPS: -0.46; EPS growth quarter/prev quarter: -3.90%;

EPS growth this year: 25.90%; EPS growth past 5 years: 11.80%;

EPS ttm: -0.46;

P/S: ; P/B: 07.05; P/Cashflow: 7.89; P/FCF: ;

Sales: –; Sales growth quarter/prev quarter: ; Sales growth past 5 years: -41.60%;

Profitability:

Gross Margin: ; Profit Margin: ; Operating Margin: ;

ROA – return on assets: -142.50%; ROE – return on equity: -160.80%; LT Debt/Equity: 0.00; Total Debt/Equity: 0.00;

Dividend: –; Dividend Yield (%): –;

Insider Ownership: 5.40%; Insider Transactions:10.84%;

Institutional Ownership: 6.80%; Institutional Transactions: 13.02%;

Data update: 07/10/2020.